---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-063667"
form_type: "8-K"
ticker: "BNTC"
cik: "0001808898"
company_name: "Benitec Biopharma Inc."
filed_at: "2024-03-08T23:59:59+00:00"
generated_at: "2026-06-05T00:41:36.397319+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.35
calibrated_materiality_score: 0.35
confidence: "high"
source: SEC EDGAR
---

# Benitec Biopharma grants 666,558 stock options to CEO and executive director at $5.21

## Summary
- Compensation Committee approved nonqualified options for CEO Jerel Banks (466,554 shares) and Exec. Director Megan Boston (200,004 shares).
- Exercise price of $5.21 per share equals March 6, 2024 closing price.
- Options vest in three equal annual installments; full acceleration upon change in control.
- Grants made under the Company's 2020 Equity and Incentive Compensation Plan.

## SEC filing metadata
- accession: 0001193125-24-063667
- form_type: 8-K
- ticker: BNTC
- cik: 0001808898
- company_name: Benitec Biopharma Inc.
- filed_at: 2024-03-08T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.35
- calibrated_materiality_score: 0.35
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1808898/000119312524063667/0001193125-24-063667-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1808898/000119312524063667/d782153d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-063667
- JSON: https://secwatch.observer/filing/0001193125-24-063667.json
- Plain text: https://secwatch.observer/filing/0001193125-24-063667.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.